Baidu
map

风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

收藏图| 风湿免疫病的服药时间手册！

2021-11-07 网络 网络

痛风类风湿性关节炎服药时间
关注

一图读懂风湿科常用药物的服用时间！

图片
图片
图片

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670459, encodeId=b1a716e04594c, content=<a href='/topic/show?id=e2d110081540' target=_blank style='color:#2F92EE;'>#风湿免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100815, encryptionId=e2d110081540, topicName=风湿免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e49426693780, createdName=nakerunner, createdTime=Wed Oct 05 04:57:59 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041788, encodeId=a8a72041e882c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 31 03:57:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187488, encodeId=2937118e48808, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eof7QgiaM40Cbk9nEupXmSOY1ibC6icYDYgtF7MMZoDnic7g0cyKqthJ2NLxE1WSiaib43H9DE4iaNQPFUBg/132, createdBy=9f9f5279032, createdName=李继鹏, createdTime=Sun Jan 23 17:35:23 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599013, encodeId=330e1599013ac, content=<a href='/topic/show?id=689560e665a' target=_blank style='color:#2F92EE;'>#服药时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60766, encryptionId=689560e665a, topicName=服药时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2e18676206, createdName=chenzhuanggui, createdTime=Tue Nov 09 01:57:59 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067848, encodeId=fe40106e84897, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Sun Nov 07 17:49:22 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-10-05 nakerunner

    #风湿免疫#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1670459, encodeId=b1a716e04594c, content=<a href='/topic/show?id=e2d110081540' target=_blank style='color:#2F92EE;'>#风湿免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100815, encryptionId=e2d110081540, topicName=风湿免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e49426693780, createdName=nakerunner, createdTime=Wed Oct 05 04:57:59 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041788, encodeId=a8a72041e882c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 31 03:57:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187488, encodeId=2937118e48808, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eof7QgiaM40Cbk9nEupXmSOY1ibC6icYDYgtF7MMZoDnic7g0cyKqthJ2NLxE1WSiaib43H9DE4iaNQPFUBg/132, createdBy=9f9f5279032, createdName=李继鹏, createdTime=Sun Jan 23 17:35:23 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599013, encodeId=330e1599013ac, content=<a href='/topic/show?id=689560e665a' target=_blank style='color:#2F92EE;'>#服药时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60766, encryptionId=689560e665a, topicName=服药时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2e18676206, createdName=chenzhuanggui, createdTime=Tue Nov 09 01:57:59 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067848, encodeId=fe40106e84897, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Sun Nov 07 17:49:22 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-05-31 heli0118

    #免疫病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1670459, encodeId=b1a716e04594c, content=<a href='/topic/show?id=e2d110081540' target=_blank style='color:#2F92EE;'>#风湿免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100815, encryptionId=e2d110081540, topicName=风湿免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e49426693780, createdName=nakerunner, createdTime=Wed Oct 05 04:57:59 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041788, encodeId=a8a72041e882c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 31 03:57:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187488, encodeId=2937118e48808, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eof7QgiaM40Cbk9nEupXmSOY1ibC6icYDYgtF7MMZoDnic7g0cyKqthJ2NLxE1WSiaib43H9DE4iaNQPFUBg/132, createdBy=9f9f5279032, createdName=李继鹏, createdTime=Sun Jan 23 17:35:23 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599013, encodeId=330e1599013ac, content=<a href='/topic/show?id=689560e665a' target=_blank style='color:#2F92EE;'>#服药时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60766, encryptionId=689560e665a, topicName=服药时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2e18676206, createdName=chenzhuanggui, createdTime=Tue Nov 09 01:57:59 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067848, encodeId=fe40106e84897, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Sun Nov 07 17:49:22 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-01-23 李继鹏

    非常好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1670459, encodeId=b1a716e04594c, content=<a href='/topic/show?id=e2d110081540' target=_blank style='color:#2F92EE;'>#风湿免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100815, encryptionId=e2d110081540, topicName=风湿免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e49426693780, createdName=nakerunner, createdTime=Wed Oct 05 04:57:59 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041788, encodeId=a8a72041e882c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 31 03:57:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187488, encodeId=2937118e48808, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eof7QgiaM40Cbk9nEupXmSOY1ibC6icYDYgtF7MMZoDnic7g0cyKqthJ2NLxE1WSiaib43H9DE4iaNQPFUBg/132, createdBy=9f9f5279032, createdName=李继鹏, createdTime=Sun Jan 23 17:35:23 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599013, encodeId=330e1599013ac, content=<a href='/topic/show?id=689560e665a' target=_blank style='color:#2F92EE;'>#服药时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60766, encryptionId=689560e665a, topicName=服药时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2e18676206, createdName=chenzhuanggui, createdTime=Tue Nov 09 01:57:59 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067848, encodeId=fe40106e84897, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Sun Nov 07 17:49:22 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2021-11-09 chenzhuanggui

    #服药时间#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1670459, encodeId=b1a716e04594c, content=<a href='/topic/show?id=e2d110081540' target=_blank style='color:#2F92EE;'>#风湿免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100815, encryptionId=e2d110081540, topicName=风湿免疫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e49426693780, createdName=nakerunner, createdTime=Wed Oct 05 04:57:59 CST 2022, time=2022-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041788, encodeId=a8a72041e882c, content=<a href='/topic/show?id=96372910100' target=_blank style='color:#2F92EE;'>#免疫病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29101, encryptionId=96372910100, topicName=免疫病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 31 03:57:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187488, encodeId=2937118e48808, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eof7QgiaM40Cbk9nEupXmSOY1ibC6icYDYgtF7MMZoDnic7g0cyKqthJ2NLxE1WSiaib43H9DE4iaNQPFUBg/132, createdBy=9f9f5279032, createdName=李继鹏, createdTime=Sun Jan 23 17:35:23 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599013, encodeId=330e1599013ac, content=<a href='/topic/show?id=689560e665a' target=_blank style='color:#2F92EE;'>#服药时间#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60766, encryptionId=689560e665a, topicName=服药时间)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2e18676206, createdName=chenzhuanggui, createdTime=Tue Nov 09 01:57:59 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067848, encodeId=fe40106e84897, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Sun Nov 07 17:49:22 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2021-11-07 含子

    已阅

    0

相关资讯

Br J Pharmacol：阿米替林阻断TLR4和IL1R介导的先天免疫反应：OA和痛风的临床前和临床证据

OA的发病特点是关节软骨进行性退化，周围组织改变，包括软骨、滑膜和肌腱。

CDSR：痛风患者痛风石治疗方案的相关研究

痛风是男性最常见的炎症性关节炎，在西方国家，至少有1%的人口会受到痛风的影响。

Arthritis Rheumatol：阿那白滞素治疗痛风发作的疗效和安全性

阿那白滞素是通过基因重组技术产生的人白介素1受体拮抗剂。阿那白滞素（anakinra）目前已被批准用于治疗系统性青少年特发性关节炎和成人Still病。

EHJ：“两大金刚”别嘌呤醇与苯溴马隆在痛风患者中的相关心血管风险

痛风发作是疼痛剧烈的致失能性炎症性关节炎，通常累及单个关节，但有时也会累及2个或更多关节。

NPJM ：元基因组分析揭示肠道微生物群在痛风发病中的潜在作用

痛风是一种主要累及关节的炎症性关节炎，被认为是高血压和心血管疾病的危险因素。痛风在男性中比女性更常见，由于饮食和生活方式的改变，痛风的患病率有所上升。

Front Immunol：痛风增加银屑病患者心血管疾病的风险

银屑病(PSO)是一种常见的全身性慢性炎症性疾病。据估计，全球约有1.25亿人患有PSO。

Baidu
map
Baidu
map
Baidu
map